Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease. FOSFASTUR study
Copyright © 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Alterations in bone and mineral metabolism are very common in chronic kidney disease (CKD). The increase in phosphate levels leads to bone disease, risk of calcification and greater mortality, so any strategy aimed at reducing them should be welcomed. The latest drug incorporated into the therapeutic arsenal to treat hyperphosphataemia in CKD is sucroferric oxyhydroxide (SFO).
OBJECTIVE: To analyse the efficacy and safety of SFO in 3 cohorts of patients, one with advanced CKD not on dialysis, another on peritoneal dialysis and the last on haemodialysis, followed for 6 months.
METHODS: A prospective, observational, multicentre study in clinical practice. Clinical and epidemiological variables were analysed. The evolution of parameters relating to alterations in bone and mineral metabolism and anaemia was analysed.
RESULTS: Eighty-five patients were included in the study (62±12 years, 64% male, 34% diabetic), 25 with advanced CKD not on dialysis, 25 on peritoneal dialysis and lastly, 35 on haemodialysis. In 66 patients (78%), SFO was the first phosphate binder; in the other 19, SFO replaced a previous phosphate binder due to poor tolerance or efficacy. The initial dose of SFO was 964±323mg/day. Overall, serum phosphate levels saw a significant reduction at 3 months of treatment (19.6%; P<.001). There were no differences in the efficacy of the drug when the different populations analysed were compared. Over the course of the study, there were no changes to levels of calcium, PTHi, ferritin, transferrin saturation index or haemoglobin, although there was a tendency for the last 2 to increase. Twelve patients (14%) withdrew from follow-up, 10 due to gastrointestinal adverse effects (primarily diarrhoea) and 2 were lost to follow-up (kidney transplant). The mean dose of the drug that the patients received increased over time, up to 1,147±371mg/day.
CONCLUSIONS: SFO is an effective option for the treatment of hyperphosphataemia in patients with CKD both in the advanced phases of the disease and on dialysis. We found similar efficacy across the 3 groups analysed. The higher their baseline phosphate level, the greater the reduction in the serum levels. A notable reduction in phosphate levels can be achieved with doses of around 1,000mg/day. Diarrhoea was the most common side effect, although it generally was not significant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Nefrologia - 41(2021), 1 vom: 01. Jan., Seite 45-52 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Eficacia y seguridad de oxihidróxido sucroférrico en el tratamiento de la hiperfosforemia en la enfermedad renal crónica. Estudio FOSFASTUR |
|---|
| Beteiligte Personen: |
Sanchez-Alvarez, J Emilio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.10.2021 Date Revised 08.10.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.nefro.2020.06.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31805809X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31805809X | ||
| 003 | DE-627 | ||
| 005 | 20231225164549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nefro.2020.06.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM31805809X | ||
| 035 | |a (NLM)33239181 | ||
| 035 | |a (PII)S0211-6995(20)30136-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanchez-Alvarez, J Emilio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease. FOSFASTUR study |
| 246 | 3 | 3 | |a Eficacia y seguridad de oxihidróxido sucroférrico en el tratamiento de la hiperfosforemia en la enfermedad renal crónica. Estudio FOSFASTUR |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.10.2021 | ||
| 500 | |a Date Revised 08.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Alterations in bone and mineral metabolism are very common in chronic kidney disease (CKD). The increase in phosphate levels leads to bone disease, risk of calcification and greater mortality, so any strategy aimed at reducing them should be welcomed. The latest drug incorporated into the therapeutic arsenal to treat hyperphosphataemia in CKD is sucroferric oxyhydroxide (SFO) | ||
| 520 | |a OBJECTIVE: To analyse the efficacy and safety of SFO in 3 cohorts of patients, one with advanced CKD not on dialysis, another on peritoneal dialysis and the last on haemodialysis, followed for 6 months | ||
| 520 | |a METHODS: A prospective, observational, multicentre study in clinical practice. Clinical and epidemiological variables were analysed. The evolution of parameters relating to alterations in bone and mineral metabolism and anaemia was analysed | ||
| 520 | |a RESULTS: Eighty-five patients were included in the study (62±12 years, 64% male, 34% diabetic), 25 with advanced CKD not on dialysis, 25 on peritoneal dialysis and lastly, 35 on haemodialysis. In 66 patients (78%), SFO was the first phosphate binder; in the other 19, SFO replaced a previous phosphate binder due to poor tolerance or efficacy. The initial dose of SFO was 964±323mg/day. Overall, serum phosphate levels saw a significant reduction at 3 months of treatment (19.6%; P<.001). There were no differences in the efficacy of the drug when the different populations analysed were compared. Over the course of the study, there were no changes to levels of calcium, PTHi, ferritin, transferrin saturation index or haemoglobin, although there was a tendency for the last 2 to increase. Twelve patients (14%) withdrew from follow-up, 10 due to gastrointestinal adverse effects (primarily diarrhoea) and 2 were lost to follow-up (kidney transplant). The mean dose of the drug that the patients received increased over time, up to 1,147±371mg/day | ||
| 520 | |a CONCLUSIONS: SFO is an effective option for the treatment of hyperphosphataemia in patients with CKD both in the advanced phases of the disease and on dialysis. We found similar efficacy across the 3 groups analysed. The higher their baseline phosphate level, the greater the reduction in the serum levels. A notable reduction in phosphate levels can be achieved with doses of around 1,000mg/day. Diarrhoea was the most common side effect, although it generally was not significant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Captores de fósforo | |
| 650 | 4 | |a Diálisis peritoneal | |
| 650 | 4 | |a Haemodialysis | |
| 650 | 4 | |a Hemodiálisis | |
| 650 | 4 | |a Hiperfosforemia | |
| 650 | 4 | |a Hyperphosphataemia | |
| 650 | 4 | |a Oxihidróxido sucroférrico | |
| 650 | 4 | |a Peritoneal dialysis | |
| 650 | 4 | |a Phosphate binders | |
| 650 | 4 | |a Sucroferric oxyhydroxide | |
| 700 | 1 | |a Astudillo Cortes, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Seras Mozas, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a García Castro, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo Ordoñez, Carlos Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade López, Ana Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ulloa Clavijo, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Gallardo Pérez, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Suárez, Carmen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nefrologia |d 2018 |g 41(2021), 1 vom: 01. Jan., Seite 45-52 |w (DE-627)NLM270991409 |x 2013-2514 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:45-52 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nefro.2020.06.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 1 |b 01 |c 01 |h 45-52 | ||